In an exclusive conversation with Deccan Chronicle, Dr. G Vikram Kumar sheds light on the complexities of hemophilia, its impact on patients’ lives, and the recent breakthroughs in the ...

As many as 30% of people living with severe hemophilia A develop inhibitors such as TFPI, which can be produced by the body’s immune response to clotting factors in replacement therapy, often limiting ...

Be Biopharma, Inc. ("Be Bio" or "the Company"), a leader in the discovery and development of engineered B Cell Medicines (BCMs), today announced key milestones alongside a new round of funding as its ...

An editorial by Fyodor Urnov lays out the urgent case for major reform in the regulatory appraisal of clinical therapies involving CRISPR gene therapies.